GSK divests thrombosis brands, related manufacturing to Aspen for £700m
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the related Notre-Dame de Bondeville (NDB) manufacturing site, to Aspen – a South African pharmaceuticals company – for £700m in cash, of which £100m relates to inventory.